<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-5633</journal-id>
<journal-title><![CDATA[Revista Colombiana de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Colomb. Cardiol.]]></abbrev-journal-title>
<issn>0120-5633</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Colombiana de Cardiologia. Oficina de Publicaciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-56332023000500257</article-id>
<article-id pub-id-type="doi">10.24875/rccar.22000107</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[La insuficiencia cardíaca crónica propicia la aparición de diabetes mellitus tipo 2]]></article-title>
<article-title xml:lang="en"><![CDATA[Chronic heart failure fosters the onset of type 2 diabetes mellitus]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Márquez-Salom]]></surname>
<given-names><![CDATA[Gustavo A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Márquez-Zuccardi]]></surname>
<given-names><![CDATA[Álvaro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Márquez-Fernández]]></surname>
<given-names><![CDATA[Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro de atención a personas con diabetes CAIAD, Sincelejo Departamento Médico ]]></institution>
<addr-line><![CDATA[Sucre ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2023</year>
</pub-date>
<volume>30</volume>
<numero>5</numero>
<fpage>257</fpage>
<lpage>262</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-56332023000500257&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-56332023000500257&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-56332023000500257&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La insuficiencia cardíaca crónica (IC) propicia la aparición de diabetes mellitus tipo 2 (DM2) y este hecho es poco conocido y entendido. El propósito de este artículo es revisar los mecanismos que se activan en la IC para inducir la aparición de la diabetes mellitus 2, sus implicaciones cardio-metabólicas y los factores de riesgo identificados, como aporte necesario a la escasa información disponible en publicaciones médicas. La resistencia a la insulina, la inflamación, el estrés oxidativo y la vasoconstricción sistémica están directamente orquestadas desde el corazón en IC. El tratamiento actual de la insuficiencia cardíaca con fracción de eyección ventricular izquierda reducida (FEVIr) fundamentado en inhibidores del cotransportador sodio glucosa tipo 2 (iSGTL2), beta-bloqueadores, inhibidor del receptor de angiotensina/neprilisina (IRAN)/IECA/ARA II y antagonistas del receptor mineralocorticoide, podría tener implicaciones favorables para evitar el desarrollo de diabetes mellitus en pacientes con insuficiencia cardíaca crónica, aunque no hay aún respaldo suficiente en la evidencia disponible, quizá por la falta de reconocimiento del problema expuesto.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Chronic heart failure (HF) fosters the onset of type 2 diabetes mellitus, and this is a little known and understood fact. The purpose of this article is to review the mechanisms that are activated in HF to induce the onset of type 2 diabetes mellitus, its cardio-metabolic implications, and the identified risk factors, as a necessary contribution to the scant available information in medical publications. Insulin resistance, inflammation, oxidative stress and systemic vasoconstriction are directly orchestrated by the heart in HF. The current treatment for heart failure with reduced ejection fraction (HFrEF), based on sodium-glucose transport protein 2 (SGLT2) inhibitors, angiotensin receptor-neprilysin inhibitors (ARNIs)/ACE inhibitors/ARBs and mineralocorticoid receptor antagonists, could have beneficial effects for preventing the onset of diabetes mellitus in patients with chronic HF, although the available evidence does not yet provide sufficient support, perhaps due to a lack of recognition of this problem.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Insuficiencia cardíaca crónica]]></kwd>
<kwd lng="es"><![CDATA[Resistencia a la insulina]]></kwd>
<kwd lng="es"><![CDATA[Inflamación]]></kwd>
<kwd lng="es"><![CDATA[Estrés oxidativo]]></kwd>
<kwd lng="es"><![CDATA[Diabetes mellitus tipo 2]]></kwd>
<kwd lng="es"><![CDATA[Tejido adiposo blanco visceral]]></kwd>
<kwd lng="en"><![CDATA[Heart failure]]></kwd>
<kwd lng="en"><![CDATA[Insulin resistance]]></kwd>
<kwd lng="en"><![CDATA[Inflammation]]></kwd>
<kwd lng="en"><![CDATA[Oxidative stress]]></kwd>
<kwd lng="en"><![CDATA[Diabetes mellitus Type 2]]></kwd>
<kwd lng="en"><![CDATA[Visceral white adipose tissue]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DeFronzo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Banting Lecture. From the triumvirate to the ominous octet:a new paradigm for the treatment of type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Diabetes]]></source>
<year>2009</year>
<volume>58</volume>
<page-range>773-95</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Price]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Krokfors]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Guglielmo]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Selective mobilization of fatty acids from adipose tissue in migratory birds]]></article-title>
<source><![CDATA[The Journal of Experimental Biology]]></source>
<year>2008</year>
<volume>211</volume>
<page-range>29-34</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miranda]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Tovar]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Palacios]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La AMPK como un sensor de energía celular y su función en el organismo]]></article-title>
<source><![CDATA[Revista de Investigación Clínica]]></source>
<year>2007</year>
<volume>59</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>458-69</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cahill Jr]]></surname>
<given-names><![CDATA[GF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fuel metabolism in starvation]]></article-title>
<source><![CDATA[Annu Rev Nutr]]></source>
<year>2006</year>
<volume>26</volume>
<page-range>1-22</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cotter]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Schugar]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ketone body metabolism and cardiovascular disease]]></article-title>
<source><![CDATA[Am J Physiol Heart Circ Physiol]]></source>
<year>2013</year>
<volume>304</volume>
<page-range>H1060-76</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferrannini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mark]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mayoux]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CV Protection in the EMPA-REG OUTCOME Trial:A &#8220;Thrifty Substrate&#8221;Hypothesis]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2016</year>
<volume>39</volume>
<page-range>1108-14</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shimizu]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshida]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Katsuno]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tateno]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Okada]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Moriya]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure]]></article-title>
<source><![CDATA[Cell Metabolism]]></source>
<year>2012</year>
<volume>15</volume>
<page-range>51-64</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bordicchia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sarzani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and humandipocytes]]></article-title>
<source><![CDATA[Clin Invest]]></source>
<year>2012</year>
<volume>122</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1022-36</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roche]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes de tipo 2:gluco-lipo-toxicidad y disfunción de la célula B pancreática]]></article-title>
<source><![CDATA[Ars Pharmaceutica]]></source>
<year>2003</year>
<volume>44</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>313-32</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yusuf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ostergren]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Gerstein]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Pfeffer]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Swedberg]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Granger]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
</person-group>
<collab>On behalf of the Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity Program (CHARM) Investigators</collab>
<article-title xml:lang=""><![CDATA[Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2005</year>
<volume>112</volume>
<page-range>48-53</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Kakkar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[McCarthy]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Januzzi]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inflammation in heart failure]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2020</year>
<volume>75</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1324-40</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gutiérrez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mecanismos fisiopatogénicos de la falla cardíaca crónica]]></article-title>
<source><![CDATA[Rev Hosp Gral &#8220;Dr. M Gea González&#8221;]]></source>
<year>2001</year>
<volume>4</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>75-95</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Márquez-Salom]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Diez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PPAR and local renin-angiotensin systems in cardiovascular and metabolic diseases associated with obesity:A unifyng Hypothesis]]></article-title>
<source><![CDATA[Open Journal of Endocrine and Metabolic Diseases]]></source>
<year>2013</year>
<volume>3</volume>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramírez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El factor de necrosis tumoral a, la resistencia a la insulina, el metabolismo de lipoproteínas y la obesidad en humanos]]></article-title>
<source><![CDATA[Nutr Hosp]]></source>
<year>2012</year>
<volume>27</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1751-7</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muniyapa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Montagnani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Koh]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Quon]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular actions of insulin]]></article-title>
<source><![CDATA[Endocrine Reviews]]></source>
<year>2007</year>
<volume>28</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>463-91</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Xian]]></surname>
<given-names><![CDATA[YK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin and b adrenergic receptor signaling:crosstalk in heart]]></article-title>
<source><![CDATA[Trends in Endocrinology &amp;Metabolism]]></source>
<year>2017</year>
<volume>28</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>416-27</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oktay]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Aktürk]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[Paul]]></surname>
<given-names><![CDATA[TK]]></given-names>
</name>
<name>
<surname><![CDATA[O'Keefe]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Ventura]]></surname>
<given-names><![CDATA[HO]]></given-names>
</name>
<name>
<surname><![CDATA[Koch]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes, cardiomyopathy, and heart failure. [Updated 2020 Aug 1]]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Feingold]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Anawalt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Boyce]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Endotext [Internet]]]></source>
<year>2000</year>
<publisher-name><![CDATA[MDText.com, Inc]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sud]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Austin]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Lipscombe]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Newton]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Tu]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Presentation blood glucose and death, hospitalization, and future diabetes risk in patients with acute heart failure síndromes]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2015</year>
<volume>36</volume>
<page-range>924-31</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tenenbaum]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Motro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fisman]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Leor]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Freimark]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Boyko]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Functional class in patients with heart failure is associated with the development of diabetes]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>2003</year>
<volume>114</volume>
<page-range>271-5</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heidenreich]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Bozkurt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Byun]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Colvin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2022 AHA/ACC/HFSA. Management of Heart Failure:A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2022</year>
<volume>145</volume>
<page-range>e895-e1032</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dyck J]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Sossalla]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hamdani]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Coronel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Light]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure:Evidence for potential off-target effects]]></article-title>
<source><![CDATA[Journal of Molecular and Cellular Cardiology]]></source>
<year>2022</year>
<volume>167</volume>
<page-range>17-31</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gliflozinas:más que antidiabéticos orales:Una breve revisión de la literatura]]></article-title>
<source><![CDATA[Rev Urug Cardiol]]></source>
<year>2021</year>
<volume>36</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CantóC]]></surname>
</name>
<name>
<surname><![CDATA[Gerhart-Hines]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Feige]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lagouge]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Noriega]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Milne]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[AMPK regulates energy expenditure by modulating NAD+metabolism and SIRT 1 actvity]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2009</year>
<volume>458</volume>
<numero>7241</numero>
<issue>7241</issue>
<page-range>1056-60</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tejedor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Corazón y riñón en la diabetes:efectos de los glucosúricos]]></article-title>
<source><![CDATA[Hipertensión y Riesgo Vascular]]></source>
<year>2020</year>
<volume>37</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>64-71</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ayers]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Byrne]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[DeMatteo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2012</year>
<volume>59</volume>
<page-range>893-8</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torp-Pedersen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Metra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Charlesworth]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Spark]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lukas]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Poole-Wilson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<collab>COMET investigators</collab>
<article-title xml:lang=""><![CDATA[Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure:data from the Carvedilol Or Metoprolol European Trial (COMET)]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2007</year>
<volume>93</volume>
<page-range>968-73</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bakris]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Bell]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Katholi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[McGill]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Phillip]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Raskin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<collab>for de GEMINI Investigators</collab>
<article-title xml:lang=""><![CDATA[The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial]]></article-title>
<source><![CDATA[Journal of Diabetes and Its Complications]]></source>
<year>2005</year>
<volume>19</volume>
<page-range>74-9</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Joseph]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Echouffo]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Effoe]]></surname>
<given-names><![CDATA[VS]]></given-names>
</name>
<name>
<surname><![CDATA[Hsueh]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
<name>
<surname><![CDATA[Allison]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Golden]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Renin-angiotensin-aldosterone system, glucose metabolism and incident type 2 diabetes mellitus:MESA]]></article-title>
<source><![CDATA[Am Heart Assoc]]></source>
<year>2018</year>
<volume>7</volume>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
